GSK pulls out of $20 billion race for Pfizer assets
1 min read . Updated: 23 Mar 2018, 02:00 PM ISTGlSK has withdrawn from the race to buy Pfizer's consumer healthcare business, the drugs firm said, endangering an auction for an asset some said could fetch as much as $20 billion
London: GlaxoSmithKline has withdrawn from the race to buy Pfizer’s consumer healthcare business, the British drugs company said on Friday, endangering an auction for an asset some said could fetch as much as $20 billion.
GSK was seen as the front runner to buy the assets, which include Advil painkillers and Centrum vitamins, after main rival Reckitt Benckiser quit the race on Thursday.
“While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation," chief executive Emma Walmsley said in a brief statement.
GSK shares jumped 4% to 13.23 pounds at 0809 GMT.
A Pfizer representative was not immediately available to comment. Reuters
Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.
